Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Morena, Marion ^a,b,c   Jaussent, Isabelle ^d   Halkovich, Aurore ^a   Dupuy, Anne Marie ^a   Bargnoux, Anne Sophie ^a,c   Chenine, Leila ^a   Leray Moragues, Hélène ^a   Klouche, Kada ^a,c   Vernhet, Hélène ^a   Canaud, Bernard ^a,b,c   Cristol, Jean Paul ^a,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b Institut de Recherche et de Formation en Dialyse   (France)

^c University Montpellier 1 et 2   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; OSTEOPROTEGERIN; PHOSPHATE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON DIALYSIS CHRONIC KIDNEY DISEASE; PHOSPHATE EXCRETION; RISK ASSESSMENT; SCORING SYSTEM; BLOOD; CALCINOSIS; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCINOSIS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RENAL DIALYSIS;

EID: 84860451056     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036175     Document Type: Article

References (36)

1. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, et al. (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-40.
2. Chiu YW, Adler SG, Budoff MJ, Takasu J, Ashai J, et al. (2010) Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 77: 1107-14.
3. Haas MH, (2010) The risk of death in patients with a high coronary calcification score: does it include predialysis patients? Kidney Int 77: 1057-9.
4. Moe SM, Chen NX, (2008) Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19: 213-6.
5. Trouvin A, Goëb V, (2010) Receptor activator of nuclear factor-kappa B ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 19: 345-354.
6. Morena M, Dupuy AM, Jaussent I, Vernhet H, Gahide G, et al. (2009) A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 24: 3389-97.
7. Nitta K, Akiba T, Uchida K, Otsubo S, Takei T, et al. (2004) Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19: 1886-9.
8. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, et al. (2010) Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 25: 2679-85.
9. Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, et al. (2006) Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 17: 1506-13.
10. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, et al. (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24: 948-955.
11. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, et al. (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-52.
12. Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, et al. (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24: 3125-31.
13. Mirza MA, Larsson A, Lind L, Larsson TE, (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205: 385-90.
14. Goolsby MJ, (2002) National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract 14: 238-42.
15. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, et al. (2005) Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type-2 diabetic patients. Diabetes Care 28: 2176-2180.
16. Maïmoun L, Couret I, Mariano-Goulart D, Dupuy AM, Cristol JP, et al. (2005) Changes in osteoprotegerin/RANKL system, bone mineral density and bone biochemical markers in patients with recent spinal cord injury. Calcified Tissue International 76: 404-411.
17. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-54.
18. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, et al. (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15: 827-32.
19. Brindis RG, Douglas PS, Hendel RC, Peterson ED, Wolk MJ, et al. (2005) ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association. J Am Coll Cardiol 46: 1587-605.
20. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, et al. (2007) ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 49: 378-402.
21. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, et al. (2003) The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42: 303-9.
22. Anand DV, Lahiri A, Lim E, Hopkins D Corder R, (2006) The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47: 1850-7.
23. Mikami S, Hamano T, Fujii N, Nagasawa Y, Isaka Y, et al. (2008) Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res 31: 1163-70.
24. Morony S, Tintut Y, Zhang Z, Cattley R, Van G, et al. (2008) Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 117: 411-20.
25. Collin-Osdoby P, (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95: 1046-57.
26. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, et al. (2001) Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276: 20659-72.
27. Shioi A, Katagi M, Okuno Y, Mori K, Jono S, et al. (2002) Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res 91: 9-16.
28. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke H, et al. (2011) FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int doi:10.1007/s00198-011-1838-0.
29. Strewler GJ, (2001) FGF23, hypophosphatemia, and rickets: has phosphatonin been found? Proc Natl Acad Sci U S A 98: 5945-6.
30. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, et al. (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-15.
31. Weber TJ, Liu S, Indridason OS, Quarles LD, (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-34.
32. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, et al. (2010) Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 107: 407-12.
33. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, et al. (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-408.
34. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE, (2004) Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 44: 1024-30.
35. Russo D, Battaglia Y, Buonanno E, (2010) Phosphorus and coronary calcification in predialysis patients. Kidney Int 78: 818; author reply 18.
36. Olauson H, Qureshi AR, Miyamoto T, Barany P, Heimburger O, et al. (2010) Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant 25: 3033-8.